Navigation Links
Kids' Vaccine Ingredient Not Likely Linked to Neurological Problems
Date:9/26/2007

CDC study finds no clear association between thimerosal, mental woes

WEDNESDAY, Sept. 26 (HealthDay News) -- The latest study on thimerosal, a preservative used in childhood immunizations, should provide parents with reassurance that exposure to the agent will not cause neuropsychological problems later on, experts say.

"We found no consistent pattern between increasing mercury exposure from birth to seven months and performance on neuropsychological tests," concluded the study's authors in the Sept. 27 New England Journal of Medicine.

Widely used before 2000, thimerosal has been the center of controversy for some years now. Some parents of autistic children believe that the mercury contained in the preservative is responsible for their children's autism.

However, the U.S. Centers for Disease Control and Prevention (CDC) maintains there is no scientific evidence of such an association. And this latest CDC study did not specifically look at links between thimerosal exposure and autism. According to the study authors, a separate CDC case-control study focused on autism and mercury exposure, is currently under way.

In 1999, the U.S Food and Drug Administration (FDA) concluded that children who were vaccinated according to the recommended childhood immunization schedule could be exposed to levels of mercury from the thimerosal contained in those vaccines that were higher than the maximum levels considered safe by the FDA.

In response, the CDC and the American Academy of Pediatrics (AAP) asked vaccine manufacturers to remove thimerosal from vaccines. That move, not surprisingly, concerned many parents who wondered if the preservative was being removed because it was harmful.

In an effort to allay some of those fears, the current CDC study looked at more than 1,000 children between the ages of 7 and 10. They compared the youngsters' neuropsychological functioning with their level of thimerosal exposure.

Using information from a three-hour neuropsychological assessment or information provided by parents and teachers, the researchers measured 42 neuropsychological outcomes, including speech, language, verbal memory, fine motor coordination, achievement, behavior regulation, tics and general intellect.

They then compared those findings to levels of thimerosal exposure, based on the child's vaccination exposure prenatally, in the first month of life, and in the first seven months of life.

"Our study does not support a causal association between early exposure to mercury from thimerosal-containing vaccines and immune globulins and deficits in neuropsychological functioning at the age of 7 to 10 years," concluded the study's authors.

That conclusion, however, seems to contradict some of the study's findings.

For example, the researchers found that boys with the highest levels of thimerosal exposure had about twice the risk of evaluator-observed tics compared to boys with the lowest exposure.

While these findings may seem disparate with this conclusion, Dr. Anne Schuchat, director of the CDC's National Center for Immunization and Respiratory Diseases, said some of the findings are likely due to chance, because such a high number of statistical comparisons were done. She was not involved in the study, which was led by William Thompson of the CDC's influenza division.

According to Schuchat, who spoke at a special CDC teleconference held Wednesday, the researchers completed 42 tests of neuropsychological functioning and completed 378 statistical comparisons from those tests.

"By chance alone, 19 of the 378 statistical tests we ran would be abnormal," she said, noting that 19 is the exact number of tests that resulted in abnormal findings.

However, 12 of those 19 tests suggested a positive outcome from higher thimerosal exposure, and seven, including the tic finding, suggested a negative outcome.

"Each test doesn't tell us as much individually," she said. "Chance alone probably explained these findings. The totality of the results are quite reassuring."

Additionally, Schuchat said there was no increase in the incidence of parent-reported tics in children with the highest thimerosal exposure, so the tics observed by the evaluators may have been transient in nature.

But several other studies have found a possible link between thimerosal exposure and tics. Because of that, the CDC feels the finding should be further explored to ensure that it was due to chance finding and not an actual effect of the preservative.

"This is what happens when you try to sub-stratify data," said Dr. Paul Offit, chief of infectious diseases at Children's Hospital of Philadelphia. "What's important is if you add up all the studies, do you find greater problems from thimerosal?" And, he said that study after study has shown that thimerosal does not cause harm.

"Parents should feel enormously reassured that another study has found that the levels of thimerosal contained in vaccines before 2001 are not harmful," said Offit, who also wrote one of two accompanying perspective pieces in the journal. Both pieces offered details on the legal history and the public health implications of the autism-vaccine controversy, even though that was not addressed in the actual study itself.

Thimerosal has already been removed from all but one vaccine, according to Schuchat. Some versions of the influenza vaccine still contain thimerosal, though thimerosal-free versions are also available, she said.

"Parents shouldn't take a theoretical risk and elevate it above the real risk of influenza. There's nothing theoretical about the dangers of influenza," Offit explained, adding that even healthy children can be at risk of serious flu complications.

"Vaccines are safe and effective. They prevent 33,000 deaths and 14 million infections annually," Schuchat said.

More information

To learn more about vaccines, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Sept. 26, 2007, CDC teleconference with Anne Schuchat, M.D., director, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, Atlanta; Paul Offit, M.D., chief of infectious diseases, Children's Hospital of Philadelphia; Sept. 27, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Researchers Scale to assess the Severity of Epilepsy in Kids
2. Snoring May Be Sign of Asthma in Kids
3. Toxin connected to Flesh-eating Pneumonia in Kids
4. Healthy snacks improve nutrition of kids
5. Kids not getting enough Physical Exercise
6. Helping Kids Attain a Healthy Weight
7. Folic Acid helps Kids with Diabetes
8. Sleep Apnea Linked to Bed-Wetting in Kids
9. Easier Dialysis for Kids
10. Nitrous Oxide for Kids
11. Few Parents Help Kids Fight Acne
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC (PER®) ... on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, 2017. ... to have Amy E. Herman present at this year’s conference, her unprecedented knowledge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New York ... participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria in ... that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise in ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. announced ... marketing agreement with development and manufacturing partner Gland ... the terms of this agreement, Breckenridge will market ... the United States . The ... ANDA. The products cover a wide range of ...
(Date:12/5/2016)... 2016  Sharn Anesthesia Inc. announced today that it ... partner for Salter Labs.  The company also received the ... of outstanding sales performance. Salter Labs is ... care, including the market gold standard ECO 2 ... of the Parker Flex-Tip® Endotracheal Tube, which is a ...
Breaking Medicine Technology: